A COVID-19 vaccine candidate developed at the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) has been administered to the first trial participants out of Halifax’s Canadian Centre for Vaccinology. Three healthy adults received the first dose of two, which will be given to 108 total participants, spaced 28 days apart and compared to a control group receiving placebo. If Phase 1 trials are successful, the next stage will see multiple trial sites across the country with the potential to complete testing in nine months if all goes well. This particular candidate has less onerous storage requirements than those currently approved for use in Canada.